[
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains a Hold on Pfizer (PFE)",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a hold rating on Pfizer Inc. (NYSE:PFE), setting a $32 price target. The company declared a $0.43 fiscal Q3 2025 dividend on June 25 on its common stock, payable September 2 […]",
    "url": "https://finnhub.io/api/news?id=6c5c12a7ddcb32c366e479c5256880c6023a1f9d4f6916cfdda4e6887699219d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752864418,
      "headline": "Morgan Stanley Maintains a Hold on Pfizer (PFE)",
      "id": 136011992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a hold rating on Pfizer Inc. (NYSE:PFE), setting a $32 price target. The company declared a $0.43 fiscal Q3 2025 dividend on June 25 on its common stock, payable September 2 […]",
      "url": "https://finnhub.io/api/news?id=6c5c12a7ddcb32c366e479c5256880c6023a1f9d4f6916cfdda4e6887699219d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program",
    "summary": "Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for Eliquis (apixaban), their top-selling blood thinner, in a move aimed at improving access for uninsured and underinsured patients. Starting September 8, 2025, eligible individuals will be able to […]",
    "url": "https://finnhub.io/api/news?id=18641e237c69da19d67780d5ef0783fd4cfce00d93cd89387f3bc600cd9cf95f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752864358,
      "headline": "Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program",
      "id": 136011993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for Eliquis (apixaban), their top-selling blood thinner, in a move aimed at improving access for uninsured and underinsured patients. Starting September 8, 2025, eligible individuals will be able to […]",
      "url": "https://finnhub.io/api/news?id=18641e237c69da19d67780d5ef0783fd4cfce00d93cd89387f3bc600cd9cf95f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial",
    "summary": "Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions. The study did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674).",
    "url": "https://finnhub.io/api/news?id=7c3ffe175d5bb70a64db9cc8c48e3420e1973fc25da6e022c9c0004df442b68e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752861253,
      "headline": "Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial",
      "id": 136011994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions. The study did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674).",
      "url": "https://finnhub.io/api/news?id=7c3ffe175d5bb70a64db9cc8c48e3420e1973fc25da6e022c9c0004df442b68e"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 20",
    "summary": "Stay informed with this week's dividend updates for Dividend Champions, Contenders, and Challengers. Read the latest updates here.",
    "url": "https://finnhub.io/api/news?id=fb47a36d1cd37dafe4908488d9baad2a56916c595c358b212819b053a5c3d074",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752861204,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 20",
      "id": 136009322,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Stay informed with this week's dividend updates for Dividend Champions, Contenders, and Challengers. Read the latest updates here.",
      "url": "https://finnhub.io/api/news?id=fb47a36d1cd37dafe4908488d9baad2a56916c595c358b212819b053a5c3d074"
    }
  },
  {
    "ts": null,
    "headline": "Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1",
    "summary": "(Bloomberg) -- President Donald Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two weeks, ramping up his push to reshape the US’s standing in the global trading system by penalizing purchases from abroad.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeMumbai Facelift Is Inspired by 200-Year-Old New York BlueprintAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homeless",
    "url": "https://finnhub.io/api/news?id=58d65d3f0f8a9363ad8c970eee84c3062854156adc24935412e4f73c5cbc94bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752856800,
      "headline": "Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1",
      "id": 136007824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two weeks, ramping up his push to reshape the US’s standing in the global trading system by penalizing purchases from abroad.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeMumbai Facelift Is Inspired by 200-Year-Old New York BlueprintAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homeless",
      "url": "https://finnhub.io/api/news?id=58d65d3f0f8a9363ad8c970eee84c3062854156adc24935412e4f73c5cbc94bf"
    }
  },
  {
    "ts": null,
    "headline": "J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?",
    "summary": "JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.",
    "url": "https://finnhub.io/api/news?id=d2a9086031965b4ec27f20fd36ef39587dbf3fb10ab06cf42c7000555d686142",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752851220,
      "headline": "J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?",
      "id": 136007863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.",
      "url": "https://finnhub.io/api/news?id=d2a9086031965b4ec27f20fd36ef39587dbf3fb10ab06cf42c7000555d686142"
    }
  },
  {
    "ts": null,
    "headline": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
    "summary": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
    "url": "https://finnhub.io/api/news?id=2264f0b1d781b24dc3e87e7e123c18cc73e712a60f4b74c0d99455fa24e51e6a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752849968,
      "headline": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
      "id": 136008446,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2264f0b1d781b24dc3e87e7e123c18cc73e712a60f4b74c0d99455fa24e51e6a"
    }
  },
  {
    "ts": null,
    "headline": "Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth",
    "summary": "The epilepsy therapeutics market is growing steadily, driven by rising global epilepsy prevalence and innovative personalized medicine approaches. Despite challenges like drug-resistant epilepsy and high costs, advancements in third-generation AEDs and online distribution channels are enhancing treatment accessibility. North America leads in revenue, while Asia-Pacific is set to experience the highest CAGR between 2025-2033, fueled by healthcare expansion and governmental support. Notable market",
    "url": "https://finnhub.io/api/news?id=6aa1af53cd5de6f7594af7f1bca8e32d34b09dd8192d7d773a584bb79ff88769",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752846840,
      "headline": "Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth",
      "id": 136005783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The epilepsy therapeutics market is growing steadily, driven by rising global epilepsy prevalence and innovative personalized medicine approaches. Despite challenges like drug-resistant epilepsy and high costs, advancements in third-generation AEDs and online distribution channels are enhancing treatment accessibility. North America leads in revenue, while Asia-Pacific is set to experience the highest CAGR between 2025-2033, fueled by healthcare expansion and governmental support. Notable market",
      "url": "https://finnhub.io/api/news?id=6aa1af53cd5de6f7594af7f1bca8e32d34b09dd8192d7d773a584bb79ff88769"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)",
    "summary": "Zoetis leads in animal health with strong EPS growth, key patent-protected drugs, and a rare value entry point. Learn why ZTS stock is upgraded to strong buy.",
    "url": "https://finnhub.io/api/news?id=02e78cf42d29f2da0a70b14a2648f4febbdc001636b97ca5b51a7f0adef87176",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752831011,
      "headline": "Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)",
      "id": 136001411,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1661329207/image_1661329207.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Zoetis leads in animal health with strong EPS growth, key patent-protected drugs, and a rare value entry point. Learn why ZTS stock is upgraded to strong buy.",
      "url": "https://finnhub.io/api/news?id=02e78cf42d29f2da0a70b14a2648f4febbdc001636b97ca5b51a7f0adef87176"
    }
  }
]